MCID: CRB037
MIFTS: 69

Cerebral Palsy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Palsy

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 12 75 53 54 29 55 6 43 3 15 38 17 72 33
Infantile Cerebral Palsy 12 72
Cerebral Palsy, Mixed 72
Mixed Cerebral Palsy 53
Palsy, Cerebral 40
Palsy Cerebral 75

Classifications:



External Ids:

Disease Ontology 12 DOID:1969
MeSH 44 D002547
NCIt 50 C34460
SNOMED-CT 68 1178005
ICD10 33 G80 G80.9
UMLS 72 C0007789 C0392549 C0751024

Summaries for Cerebral Palsy

NINDS : 54 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic cerebral palsy and inherited congenital spastic tetraplegia, and has symptoms including seizures, tremor and dystonia. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Vesicle-mediated transport and NF-KappaB Family Pathway. The drugs Levodopa and Heparin have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 53 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

MedlinePlus : 43 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Cerebral palsy (CP) is a group of disorders that affect a person's ability to move and maintain balance and posture. CP is the most common motor disability in childhood. CDC estimates that an average of 1 in 323 children in the U.S. have CP.

Wikipedia : 75 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 832)
# Related Disease Score Top Affiliating Genes
1 spastic cerebral palsy 34.9 PLP1 GAD1 F5
2 inherited congenital spastic tetraplegia 33.8 KANK1 GAD1 ADD3
3 spastic paraplegia 50, autosomal recessive 33.5 AP4S1 AP4M1 AP4B1
4 hypertonia 33.2 AP4S1 AP4M1 AP4B1
5 hereditary spastic paraplegia 51 32.9 AP4S1 AP4B1
6 spastic paraplegia 2, x-linked 32.7 PLP1 ATL1 AP4B1
7 hereditary spastic paraplegia 32.1 PLP1 ATL1 AP4M1 AP4B1
8 chorioamnionitis 31.3 TNF IL6 IL1B
9 brain injury 31.2 IL6 BDNF APOE
10 placental abruption 31.1 MTHFR F5 F2
11 traumatic brain injury 31.0 IL6 BDNF APOE
12 thrombophilia 30.9 MTHFR F5 F2
13 pre-eclampsia 30.9 MTHFR IL6 F5 F2
14 spinal cord injury 30.9 TNF IL6 BDNF
15 eclampsia 30.8 TNF MTHFR F2
16 gingivitis 30.7 TNF IL6 IL1B
17 periodontitis 30.7 TNF IL6 IL1B
18 disease of mental health 30.6 IL6 GAD1 BDNF APOE
19 sleep apnea 30.5 TNF IL6 IL1B APOE
20 bacterial vaginosis 30.5 TNF IL6 IL1B
21 toxoplasmosis 30.5 TNF IL6 IL1B
22 porencephaly 30.5 MTHFR F5 F2 COL4A1
23 cytomegalovirus infection 30.4 TNF IL6 IL1B
24 stroke, ischemic 30.4 MTHFR F5 F2 APOE
25 perinatal necrotizing enterocolitis 30.3 TNF IL6 IL1B
26 pulmonary embolism 30.3 MTHFR F5 F2
27 pyelonephritis 30.3 TNF IL6 IL1B
28 placenta disease 30.3 MTHFR IL6 IL1B F5
29 meningitis 30.3 TNF IL6 IL1B
30 schizencephaly 30.3 MTHFR F5 COL4A1
31 purpura 30.2 TNF IL6 F2
32 osteomyelitis 30.2 TNF IL6 IL1B
33 protein s deficiency 30.2 MTHFR F5 F2
34 protein c deficiency 30.2 MTHFR F5 F2
35 thrombophilia due to activated protein c resistance 30.2 MTHFR F5 F2
36 cerebral sinovenous thrombosis 30.2 F5 F2
37 homocysteinemia 30.1 MTHFR F5 F2
38 endometritis 30.1 TNF IL6 IL1B
39 thrombophilia due to thrombin defect 30.1 MTHFR F5 F2
40 antiphospholipid syndrome 30.1 MTHFR F5 F2
41 appendicitis 30.1 TNF IL6 IL1B
42 spondylitis 30.1 TNF LTA IL6
43 bacterial meningitis 30.0 TNF IL6 IL1B
44 gastroenteritis 30.0 TNF IL6 IL1B
45 bone inflammation disease 30.0 TNF IL6 IL1B
46 pertussis 30.0 TNF IL6 IL1B
47 juvenile rheumatoid arthritis 29.9 TNF LTA IL6 IL1B
48 peritonitis 29.9 TNF IL6 IL1B F2
49 otitis media 29.9 TNF IL6 IL1B
50 periodontitis, chronic 29.9 IL6 IL1B

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:


seizures, tremor, dystonia, back pain, pain, headache, abnormality of extrapyramidal motor function, involuntary movements, torticollis, muscle fibrillation, syncope, athetosis, chronic pain, asterixis, myokymia, sciatica, vertigo/dizziness, sleeplessness, muscle rigidity

MGI Mouse Phenotypes related to Cerebral Palsy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 AP4B1 AP4E1 APOE ATL1 BDNF COL4A1
2 growth/size/body region MP:0005378 10.25 AP4E1 APOE BDNF COL4A1 F2 F5
3 homeostasis/metabolism MP:0005376 10.25 AP4E1 AP4M1 APOE BDNF COL4A1 F2
4 cardiovascular system MP:0005385 10.16 ADD3 AP4E1 APOE COL4A1 F2 F5
5 nervous system MP:0003631 10.1 AP4B1 AP4E1 APOE BDNF COL4A1 F2
6 integument MP:0010771 9.97 APOE BDNF F2 F5 IL1B IL6
7 limbs/digits/tail MP:0005371 9.87 AP4E1 APOE ATL1 GAD1 LTA MTHFR
8 respiratory system MP:0005388 9.76 APOE BDNF COL4A1 F2 GAD1 IL6
9 skeleton MP:0005390 9.65 AP4E1 APOE F2 GAD1 IL1B IL6
10 vision/eye MP:0005391 9.28 AP4E1 APOE BDNF COL4A1 IL6 LTA

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levodopa Approved Phase 4 59-92-7 6047
2
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Caffeine Approved Phase 4 58-08-2 2519
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
8
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
9
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
10
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
11
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
12
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13 Dihydroxyphenylalanine Phase 4
14 Carbidopa, levodopa drug combination Phase 4
15 calcium heparin Phase 4
16 incobotulinumtoxinA Phase 4
17 Sunflower Phase 4
18 Acidophilus Phase 4
19 Central Nervous System Stimulants Phase 4
20 Citrate Phase 4
21 Purinergic P1 Receptor Antagonists Phase 4
22 Phosphodiesterase Inhibitors Phase 4
23 Chelating Agents Phase 4
24 Anticoagulants Phase 4
25 Caffeine citrate Phase 4
26 Antipyretics Phase 4
27 Analgesics Phase 4
28 Analgesics, Non-Narcotic Phase 4
29 Adrenergic alpha-2 Receptor Agonists Phase 4
30 Adrenergic Agonists Phase 4
31 Adrenergic alpha-Agonists Phase 4
32 Central Nervous System Depressants Phase 4
33 Hypnotics and Sedatives Phase 4
34 Anesthetics Phase 4
35 Adrenergic Agents Phase 4
36 Anesthetics, General Phase 4
37 Anesthetics, Intravenous Phase 4
38 Oxytocics Phase 4
39 Neuromuscular Agents Phase 4
40 Hormones Phase 4
41 Respiratory System Agents Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Hormone Antagonists Phase 4
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
45 glucocorticoids Phase 4
46 Anti-Asthmatic Agents Phase 4
47 Betamethasone Valerate Phase 4 2152-44-5
48 Betamethasone-17,21-dipropionate Phase 4
49 Betamethasone sodium phosphate Phase 4
50 Betamethasone benzoate Phase 4

Interventional clinical trials:

(show top 50) (show all 925)
# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 Changes of Gas Values in Cord Blood Versus Time and Temperature Unknown status NCT02785367 Phase 4
5 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
6 A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
7 Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study Completed NCT01955655 Phase 4 Baclofen
8 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies. A Prospective, Randomized and Double-blinded Study Completed NCT00964639 Phase 4 Ropivacaine;Saline
9 Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
10 A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
11 SPREAD AND EFFECTIVENESS OF BOTULINUM NEUROTOXIN A IN SPASTIC EQUINUS IN CEREBRAL PALSY:SHORT-TERM STUDY Completed NCT01276015 Phase 4 Botulinum Toxin Type A
12 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
13 Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation Completed NCT03117322 Phase 4
14 Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate Completed NCT00120588 Phase 4 magnesium
15 Magnetic Resonance Imaging and Neurodevelopmental Outcomes in Preterm Infants Following Administration of High-Dose Caffeine - A Pilot Study Completed NCT00809055 Phase 4 Caffeine citrate
16 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
17 Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy Recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
18 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
19 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
20 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
21 Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor: a Multicenter Randomized Controlled Trial Not yet recruiting NCT03991091 Phase 4 discontinuation of oxytocin administration;continuation of oxytocin administration
22 Improvement After Botulinum Toxin A Injections to the Upper Extremities in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
23 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
24 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
25 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
26 Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities Unknown status NCT00202761 Phase 2, Phase 3
27 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01832454 Phase 2, Phase 3
28 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
29 Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy Unknown status NCT01633736 Phase 3
30 Magnesium Prevention of Brain Injury in Preterm Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
31 Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial Unknown status NCT01189058 Phase 2, Phase 3
32 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS Unknown status NCT02154152 Phase 3 Homoeopathic Medicine causticum 200c
33 Effectiveness of Vojta Therapy in Motor Development of Preterm Children Unknown status NCT01838278 Phase 3
34 Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of "Botulax®" Versus "Botox®" in Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
35 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
36 Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
37 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT00261131 Phase 3 Botulinum Toxin A
38 Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy Completed NCT01527162 Phase 3
39 Effectiveness of Intermittent Serial Casting on Spastic Wrist Flexion Deformity in Children With Cerebral Palsy Treated By Botulinum Toxin A Completed NCT03306212 Phase 3 Botulinum toxin A
40 Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) Completed NCT00014989 Phase 3 magnesium sulfate
41 A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01251380 Phase 3
42 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Children With Cerebral Paralysis Completed NCT01929434 Phase 3
43 A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01249417 Phase 3 Placebo
44 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
45 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT02002884 Phase 3 IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight)
46 Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
47 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
48 A Six-Month, Multi-Center, Open-Label Study to Assess the Safety and Efficacy of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
49 Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy and Death in Preterm Infants (MASP-STUDY) Completed NCT01492608 Phase 3 Magnesium sulphate
50 Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Children and Adolescents (2-17 Years) With Chronic Troublesome Sialorrhea Associated With Neurological Disorders, and/or Intellectual Disability Completed NCT02270736 Phase 3 IncobotulinumtoxinA;Placebo

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Baclofen
Dantrolene
Dantrolene Sodium

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 29

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

41
Brain, Testes, Bone, Spinal Cord, Heart, Lung, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 20670)
# Title Authors PMID Year
1
Inflammatory markers in the saliva of cerebral palsy individuals with gingivitis after periodontal treatment. 38 17
31269113 2019
2
Rehabilitation with a combination of scalp acupuncture and exercise therapy in spastic cerebral palsy. 38 17
31003673 2019
3
Use of whole body vibration therapy in individuals with moderate severity of cerebral palsy- a feasibility study. 38 17
31043157 2019
4
Identification of proteolipid protein 1 gene duplication by multiplex ligation-dependent probe amplification: first report of genetically confirmed family of Pelizaeus-Merzbacher disease in Korea. 9 38
18437021 2008
5
Reaching movements in childhood dystonia contain signal-dependent noise. 9 38
15996397 2005
6
The Xq22 inversion breakpoint interrupted a novel Ras-like GTPase gene in a patient with Duchenne muscular dystrophy and profound mental retardation. 9 38
12145744 2002
7
Amniotic fluid matrix metalloproteinase-8 and the development of cerebral palsy. 9 38
12235718 2002
8
Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain. 9 38
11477207 2001
9
Racial differences in skeletal fragility but not osteoarthritis among women and men with cerebral palsy. 38
31417943 2019
10
Visuo-haptic transfer for object recognition in children with periventricular leukomalacia and bilateral cerebral palsy. 38
31017037 2019
11
Biofeedback interventions for individuals with cerebral palsy: a systematic review. 38
29756481 2019
12
Low bone mineral density in ambulatory persons with cerebral palsy? A systematic review. 38
29783868 2019
13
The impact of time of delivery on gestations complicated by preterm premature rupture of membranes: daytime versus nighttime. 38
29631461 2019
14
High prevalence of pituitary hormone deficiency in both unilateral and bilateral optic nerve hypoplasia. 38
30740788 2019
15
Is Cerebral Palsy Changing in High Resource Settings? Data From the Quebec Cerebral Palsy Registry. 38
31074324 2019
16
Control of Walking Speed in Children With Cerebral Palsy. 38
31393305 2019
17
The Hand Assessment for Infants at risk for cerebral palsy. 38
30740667 2019
18
Preoperative botulinum neurotoxin A for children with bilateral cerebral palsy undergoing major hip surgery: a randomized double-blind placebo-controlled trial. 38
30644541 2019
19
Getting inTOUCH: outcomes of a knowledge translation intervention for tactile assessment knowledge, barriers, and practice in paediatric therapists working with children with cerebral palsy. 38
29693473 2019
20
Content validation of the Quality of Life Inventory-Disability. 38
31163096 2019
21
Pre- and Postoperative Gait Analysis and Video for Selective Dorsal Rhizotomy in Spastic Diplegia: 2-Dimensional Operative Video. 38
30590806 2019
22
Very preterm children at risk for developmental coordination disorder have brain alterations in motor areas. 38
30891804 2019
23
Effects of salivary gland botulinum Toxin-A on drooling and respiratory morbidity in children with neurological dysfunction. 38
31185343 2019
24
Hand Assessment for Infants: normative reference values. 38
30719697 2019
25
The effect of femoral orientation on the measurement of the head shaft angle: an ex-vivo study. 38
30789536 2019
26
Guided Growth of the Proximal Femur for the Management of Hip Dysplasia in Children With Cerebral Palsy. 38
31393306 2019
27
Preterm children with suspected cerebral palsy at 19 months corrected age in the Canadian neonatal follow-up network. 38
31271995 2019
28
Upper limb strength training and somatosensory stimulation: optimizing self-care independence for children with unilateral cerebral palsy. 38
30888051 2019
29
Preoperative treatment of spasticity with botulinum neurotoxin A to reduce pain in cerebral palsy: is it worthwhile? 38
30761520 2019
30
Impact of Ankle-Foot Orthosis on Gait Efficiency in Ambulatory Children With Cerebral Palsy: A Systematic Review and Meta-analysis. 38
30920399 2019
31
Long-term prognosis of epilepsy in patients with cerebral palsy. 38
30854645 2019
32
What makes children with cerebral palsy vulnerable to malnutrition? Findings from the Bangladesh cerebral palsy register (BCPR). 38
29658318 2019
33
Should Proximal Femoral Implants be Removed Prophylactically or Reactively in Children With Cerebral Palsy? 38
31393307 2019
34
Treatment and re/habilitation of children with cerebral palsy in India: a scoping review. 38
30883735 2019
35
Reliability of the Motor Learning Strategies Rating Instrument in physiotherapy intervention for children with cerebral palsy. 38
30740648 2019
36
Quantifying motor learning strategies can translate to physiotherapy dose for children with cerebral palsy. 38
30761519 2019
37
Upper limb impairments, process skills, and outcome in children with unilateral cerebral palsy. 38
30775778 2019
38
Constipation, antiepileptic drugs, and gingivitis in children and adolescents with cerebral palsy. 38
30817037 2019
39
Discriminant ability and criterion validity of the Trunk Impairment Scale for cerebral palsy. 38
29663838 2019
40
Activity training on the ground in children with cerebral palsy: Systematic review and meta-analysis. 38
29659303 2019
41
Interventions for management of respiratory disease in young people with cerebral palsy: A systematic review. 38
31276598 2019
42
Beyond stereotypes of cerebral palsy: Exploring the lived experiences of young Canadians. 38
31297831 2019
43
Barriers to recruitment of children with cerebral palsy in a trial of home-based training. 38
31198879 2019
44
Incidence of osteoarthritis, osteoporosis and inflammatory musculoskeletal diseases in adults with cerebral palsy: A population-based cohort study. 38
31075418 2019
45
Mobility and self-care trajectories for individuals with cerebral palsy (aged 1-21 years): a joint longitudinal analysis of cohort data from the Netherlands and Canada. 38
31178370 2019
46
Laparoscopic fundoplication for a child with abdominal intrathecal Baclofen pump. 38
31430037 2019
47
As-indicated versus routine vision screening of preterm children: a 17-year retrospective regional study. 38
31421027 2019
48
Early-onset fetal growth restriction: a systematic review on mortality and morbidity. 38
31376293 2019
49
Mental health disorders, participation, and bullying in children with cerebral palsy. 38
30710352 2019
50
Serious game-based intervention for children with developmental disabilities. 38
31393252 2019

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ADD3 NM_001320591.2(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 10:111882007-111882007 10:110122249-110122249
2 46;XX;t(1;5)(p31;q33)dn Translocation Likely pathogenic
3 46;XY;t(6;16)(p21.1;q21)dn Translocation Uncertain significance

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 F5 COL4A1 APOE AP4S1 AP4M1 AP4E1
2
Show member pathways
12.64 TNF LTA IL6 IL1B BDNF
3
Show member pathways
12.33 AP4S1 AP4M1 AP4E1 AP4B1
4
Show member pathways
12.19 TNF LTA IL6 IL1B BDNF
5
Show member pathways
11.99 TNF LTA IL6 IL1B
6 11.98 TNF PLP1 IL6 IL1B BDNF
7 11.93 AP4S1 AP4M1 AP4E1 AP4B1
8 11.84 TNF LTA IL1B
9 11.84 TNF LTA IL6 IL1B
10 11.83 TNF IL6 IL1B
11 11.8 TNF IL6 IL1B
12 11.78 TNF IL6 IL1B COL4A1
13 11.77 TNF IL6 IL1B COL4A1
14
Show member pathways
11.77 TNF MTHFR IL6 IL1B F2 APOE
15
Show member pathways
11.76 TNF IL6 IL1B F2 COL4A1
16 11.73 TNF LTA IL1B
17 11.69 TNF IL6 IL1B
18 11.68 TNF IL6 IL1B
19 11.63 TNF IL6 IL1B COL4A1 BDNF
20
Show member pathways
11.6 TNF IL6 IL1B
21 11.6 TNF IL6 IL1B
22 11.56 TNF IL6 IL1B BDNF
23 11.53 TNF IL6 IL1B
24 11.46 TNF IL6 IL1B
25 11.46 TNF IL6 IL1B
26 11.29 TNF IL6 IL1B
27 11.28 TNF IL6 IL1B
28 11.28 TNF IL6 IL1B APOE
29 11.21 TNF IL6 IL1B
30 11.15 TNF IL6 IL1B
31 11.14 TNF LTA IL6 IL1B
32 10.95 TNF LTA IL6 IL1B COL4A1 BDNF
33 10.89 TNF IL6 COL4A1
34 10.42 TNF MTHFR IL6 IL1B

GO Terms for Cerebral Palsy

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 TNF LTA IL6 IL1B F5 F2
2 endoplasmic reticulum lumen GO:0005788 9.65 IL6 F5 F2 COL4A1 APOE
3 trans-Golgi network membrane GO:0032588 9.46 AP4S1 AP4M1 AP4E1 AP4B1
4 endosome lumen GO:0031904 9.26 AP4S1 AP4M1 AP4E1 AP4B1
5 AP-4 adaptor complex GO:0030124 8.92 AP4S1 AP4M1 AP4E1 AP4B1
6 extracellular region GO:0005576 10.02 TNF LTA IL6 IL1B F5 F2

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.88 IL6 F5 F2 APOE
2 defense response to Gram-positive bacterium GO:0050830 9.79 TNF LTA IL6
3 positive regulation of interleukin-6 production GO:0032755 9.72 TNF IL6 IL1B
4 humoral immune response GO:0006959 9.71 TNF LTA IL6
5 positive regulation of interferon-gamma production GO:0032729 9.67 TNF LTA IL1B
6 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.62 TNF IL1B
7 negative regulation of growth of symbiont in host GO:0044130 9.62 TNF LTA
8 protein localization GO:0008104 9.62 AP4S1 AP4M1 AP4E1 AP4B1
9 locomotory exploration behavior GO:0035641 9.61 GAD1 APOE
10 negative regulation of platelet activation GO:0010544 9.6 F2 APOE
11 negative regulation of lipid storage GO:0010888 9.59 TNF IL6
12 response to glucocorticoid GO:0051384 9.58 TNF IL6
13 positive regulation of chemokine biosynthetic process GO:0045080 9.57 TNF IL1B
14 regulation of establishment of endothelial barrier GO:1903140 9.56 TNF IL1B
15 negative regulation of neurogenesis GO:0050768 9.54 TNF IL6 IL1B
16 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.52 TNF LTA
17 positive regulation of fever generation GO:0031622 9.51 TNF IL1B
18 sequestering of triglyceride GO:0030730 9.48 TNF IL1B
19 protein targeting GO:0006605 9.46 AP4S1 AP4M1 AP4E1 AP4B1
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IL1B
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.43 TNF IL1B APOE
22 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.4 TNF LTA
23 chronic inflammatory response to antigenic stimulus GO:0002439 9.16 TNF
24 positive regulation of neuroinflammatory response GO:0150078 9.13 TNF IL6 IL1B
25 positive regulation of glial cell proliferation GO:0060252 8.92 TNF LTA IL6 IL1B

Molecular functions related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF LTA IL6 IL1B

Sources for Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....